FirmaIQ
Org.nr 985 889 635 AS · OSLO · 72.100 Forskning og eksperimentell utvikling innenfor naturvitenskap og teknikk Sandakerveien 138, 0484 OSLO Latest filing: Årsregnskap 2025 · approved 14.04.2026 · journal 2026 688329 Analysis generated: 09 Sep 2026 · Auto-onboard

LYTIX BIOPHARMA ASA

LYTIX BIOPHARMA ASA · 23 published annual accounts (2003–2025). Latest year revenue 11.1k NOK, net result -60.0m NOK, equity 61.8m NOK, cash 10.6m NOK. Figures from Brønnøysund årsregnskapskopi / nøkkeltall.

Auto summary · grounded in R2003–R2025
Reported fact Calculated Interpretation Unknown

Smart Search OSINT dossier

Simple version

Explain it like I’m ten

Numbers from the 2025 accounts. [R2025]

How much they sold
About 11.1k

Operating income / revenue in 2025.

Did they make money?
-60.0m

Net result for 2025.

What’s left in the company
Equity 61.8m

Book equity at year-end.

Cash
10.6m

Bank deposits and cash (when disclosed).

At a glance · 2025

Key figures

Revenue / sales
11 134
NOK · [R2025]
Net result
-59 982 000
NOK · [R2025]
Equity
61 750 000
NOK · [R2025]
Cash
10 602 000
NOK · [R2025]
Total assets
81 524 000
NOK · [R2025]
Paid-in equity
61 750 000
NOK · [R2025]

Trends

23-year arc

Charts use figures extracted from published annual reports.

Sales / revenue

Equity & cash

Cost / investment lines

Salary costs (lønnskostnader)

FTEs (årsverk)

From notes when disclosed; blank years mean not found in OCR.